PEGylated nano-graphene oxide as a nanocarrier for delivering mixed anticancer drugs to improve anticancer activity
PEGylated nano-graphene oxide as a nanocarrier for delivering mixed anticancer drugs to improve anticancer activity
复制标题
聚乙二醇化纳米氧化石墨烯作为纳米载体，用于输送混合抗癌药物以提高抗癌活性
DOI：
10.1038/s41598-020-59624-w
复制
发表时间：
2020-02-17
影响因子：
4.6
通讯作者：
Wang, Jian
中科院分区：
文献类型：
--
作者：
Pei, Xibo;Zhu, Zhou;Wang, Jian
氧化石墨烯和氧化石墨烯纳米颗粒具有较高的比表面积，在双重给药和联合化疗方面具有很大的潜力。在这里，我们开发了顺铂(铂)和阿霉素(DOX)双载药聚乙二醇化纳米氧化石墨烯(PGO)，以促进在一个系统的联合化疗。在本研究中，我们制备了约161.50 nm的纳米PgO-Pt/DOX，并用Zeta电位、原子力显微镜、透射电子显微镜、拉曼光谱、紫外-可见光谱和傅立叶变换红外光谱对其进行了表征。PgO的引入提高了铂的给药效率，最终的药物质量比优化为0.376：0.376：1。体外研究表明，PgO-铂/PgO纳米粒能有效地进入肿瘤细胞，诱导细胞明显的凋亡和坏死，并表现出比单一给药系统或游离药物更强的生长抑制作用。PGO-铂/DOX诱导的癌细胞凋亡率和坏死率最高，达18.6%，几乎是pGO-铂或pGO-DOX组的2倍。在体内的细胞凋亡和坏死象限中，数据证实，与游离药物相比，PGO-铂/DOX双给药系统减轻了铂和DOX对正常器官的毒性。肿瘤抑制数据、组织病理学观察和免疫组织化学染色证实，双药给药系统比游离药物具有更好的抗癌效果。这些结果清楚地表明，PGO-铂/DOX双给药系统为肿瘤治疗中的联合给药提供了手段。
Due to their high specific surface area, graphene oxide and graphene oxide-base nanoparticles have great potential both in dual-drug delivery and combination chemotherapy. Herein, we developed cisplatin (Pt) and doxorubicin (DOX) dual-drug-loaded PEGylated nano-graphene oxide (pGO) to facilitate combined chemotherapy in one system. In this study, nano-sized pGO-Pt/DOX ranged around 161.50 nm was fabricated and characterized using zeta-potential, AFM, TEM, Raman, UV-Vis, and FTIR analyses. The drug delivery efficacy of Pt was enhanced through the introduction of pGO, and the final weight ratio of DOX: Pt: pGO was optimized to 0.376: 0.376: 1. In vitro studies revealed that pGO-Pt/DOX nanoparticles could be effectively delivered into tumor cells, in which they induced prominent cell apoptosis and necrosis and exhibited higher growth inhibition than the single drug delivery system or free drugs. The pGO-Pt/DOX induced the most prominent cancer cell apoptosis and necrosis rate with 18.6%, which was observed almost 2 times higher than that of pGO-Pt or pGO-DOX groups. in the apoptosis and necrotic quadrants In vivo data confirmed that the pGO-Pt/DOX dual-drug delivery system attenuated the toxicity of Pt and DOX to normal organs compared to free drugs. The tumor inhibition data, histopathology observations, and immunohistochemical staining confirmed that the dual-drug delivery system presented a better anticancer effect than free drugs. These results clearly indicated that the pGO-Pt/DOX dual-drug delivery system provided the means for combination drug delivery in cancer treatment.